Hospitals and healthcare providers throughout the world are increasingly turning to cloud computing

Cloud computing refers to the availability of networks, computer software, and infrastructure that allows users to access key applications, servers, and storage. Medical services may benefit from cloud computing in a variety of ways, including the ability to store hospital or medical information simply and securely, provide test data directly to doctors, and provide easy access to doctors and patients.

 Some of the pharmaceutical industries using cloud computing are as follows: 

Pfizer

 IBM Watson and Pfizer are into a drug discovery partnership. Pfizer and IBM established a collaboration in December 2016 to speed up drug discovery in immuno-oncology. Pfizer tightened AI collaboration in May 2018. Pfizer also announced a collaboration with XtalPi, a Chinese tech firm, to investigate the molecular stability of an organic chemical and boost their drug design efforts. Pfizer developed a cloud computing tool to discover people with uncommon diseases who may have gone untreated earlier. 

Roche

 For diabetic macular oedema, a consequence of diabetes that causes a thickening of the retina and eventually blindness, Roche has developed a machine learning diagnostic approach. Roche may use its enormous clinical trial database to build AI algorithms that can predict the existence of the disease, the likelihood of disease progression, and treatment response, all of which could be given to ophthalmologists to provide more individualised care. Roche has a huge advantage in machine learning thanks to Flatiron’s large collection of cancer data. 

Novartis

Vasant Narasimhan pioneered the adoption of artificial intelligence in Novartis, leaving a global footprint for others to follow. Through AI and cloud technology, Novartis was able to understand cancer pathology pictures. Novartis teamed up with PathAI, a tech firm, to develop a system that can identify cancer. Novartis and IBM Watson collaborated on a breast cancer clinical study in June 2017. They also attempted to find trends in data, which they commonly did across many databases.

Johnson & Johnson

 According to Johnson & Johnson, newly diagnosed patients with nonvalvular atrial fibrillation (NVAF) who took XARELTO (rivaroxaban) had significantly fewer strokes, significantly fewer severe strokes, and significantly fewer stroke-related deaths than those who took warfarin with artificial intelligence. According to the study, XARELTO significantly decreased total strokes (of all severities) and drastically reduced the risk of getting the most severe strokes when compared to warfarin.

MSD

Merck (MSD) and Accenture have established a cloud-based informatics research platform in conjunction with Amazon Web Services (AWS) to boost productivity, efficiency, and creativity in the early phases of drug development. Merck Sharp & Dohme (MSD) Corp., a Merck & Co., Inc. subsidiary, has created an artificial intelligence (AI) conversation bot. Under the ‘Velocity Health’ programme, Merck and Wayra are collaborating. The Velocity Health programmes focused on healthcare prevention, with a focus on diabetes and cancer prevention.

Sanofi

Sanofi Genzyme, Sanofi’s global specialised care business unit, has teamed up with Recursion Pharmaceuticals to leverage its therapeutic repurposing technology to find new uses for Sanofi’s clinical-stage medicines across a variety of genetic illnesses. Sanofi teamed up with Exscientia to find and evaluate medication target combinations for metabolic illnesses such as diabetes through AI and cloud computing. Sanofi teamed up with BERG to evaluate possible indicators of seasonal influenza vaccination results using BERG’s patented Interrogative Biology technology.

Abbvie

Abbvie is experimenting with AI in a very stealthy manner. It does, however, have a secret project listed with Atomwise. AbbVie teamed with AiCure in September 2016 to increase adherence in an AbbVie phase 2 schizophrenia trial using an AI-based patient monitoring technology.

GlaxoSmithKline (GSK)

GSK is actively pursuing the application of artificial intelligence in drug development and has established an in-house artificial intelligence section. GSK has launched a drug discovery cooperation with Cloud Pharmaceuticals, Inc., an artificial intelligence-driven medication design and development business. Cloud will create new small-molecule therapies based on GSK’s targets. Exscientia and GSK collaborated to develop a very powerful in vivo active lead chemical that targets a unique route for the treatment of chronic obstructive pulmonary disease (COPD). 

Amgen

GNS Healthcare, a precision medicine firm, is backed by Amgen. Amgen was named as a member of MIT’s Machine Learning for Pharmaceutical Discovery and Synthesis Consortium in May 2018. Amgen also collaborates with Owkin, a medical research machine learning firm. Amgen is also a participant in the MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery) project, which will use federated learning to train machine learning models on datasets from numerous partners while maintaining each partner’s privacy.

Gilead Science

GNS, a precision medicine firm, is backed by Amgen Healthcare. In April of this year, Gilead disclosed its first public use of AI in drug research. Gilead established a strategic partnership with Insitro, a secretive company, earlier this month. The emphasis of the partnership will be nonalcoholic steatohepatitis (NASH). Gilead will employ Insitro’s technology to develop NASH disease models and identify targets that impact disease development and regression.